Compare Eli Lilly And Co (LLY) vs Toyota Motor Corp (TM) Price & Performance

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

Toyota Motor trades at $184.84, up 1.06% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while delivering consistent earnings beats. Recent U.S. sales growth and electrification progress contrast with China market challenges and production disruptions from Thailand floods.

Toyota presents a value opportunity with solid profitability and market share gains, though technical weakness and regional sales pressures warrant caution. The company's electrification investments and strong U.S. position support long-term growth, while currency risks and competitive pressures remain key monitoring points for investors.